Sona Nanotech Inc. (CSE:SONA)
 0.6400
 +0.0100 (1.59%)
  Oct 31, 2025, 1:07 PM EDT
Sona Nanotech Company Description
Sona Nanotech Inc. operates as a nanotechnology life sciences company.
It develops targeted hyperthermia and nanomedical therapies for the treatment of cancer. The company also develops gold nanoparticle products; lateral flow assay rapid tests; and bovine TB and concussion tests.
Sona Nanotech Inc. is based in Halifax, Canada.
Sona Nanotech Inc.
 
| Country | Canada | 
| Founded | 2013 | 
| Industry | Diagnostics & Research | 
| Sector | Healthcare | 
| Employees | 10 | 
| CEO | David Regan | 
Contact Details
| Address: Purdy’s Wharf Tower II Halifax, B3J 3R7 Canada | |
| Phone | 902 442 0653 | 
| Website | sonanano.com | 
Stock Details
| Ticker Symbol | SONA | 
| Exchange | Canadian Securities Exchange | 
| Fiscal Year | November - October | 
| Reporting Currency | CAD | 
| ISIN Number | CA83541C1059 | 
| SIC Code | 1000 | 
Key Executives
| Name | Position | 
|---|---|
| David Andrew Regan | Chief Executive Officer | 
| Robert William George Randall CPA | Chief Financial Officer and Corporate Secretary | 
| Dr. Len Pagliaro Ph.D. | CSO and Director | 
| Dr. Carman Giacomantonio M.D., M.Sc. | Chief Medical Officer | 
| Dr. Kulbir Singh Ph.D. | Co-Founder and Head of Research & Development | 
| Dr. Mike McAlduff | Director of Research & Development and Production and Founder | 
| Dr. Gerrard Marangoni | Co-Founder and Member of Scientific Advisory Board | 
| Darren Rowles | Head of Diagnostics |